FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308182479> ?p ?o ?g. }

• W4308182479 endingPage "12" @default.
• W4308182479 startingPage "1" @default.
• W4308182479 abstract "To determine the maximum tolerated dose (MTD) and recommended dose (RD) of orally-administered bendamustine in Japanese patients with advanced solid tumors. The optimal dosing schedule, safety, pharmacokinetics, and preliminary antitumor effects were also evaluated. A multicenter, open-label trial with a standard 3 + 3 design and dose escalation by dose-limiting toxicity (DLT) was conducted. The treatment schedules were once daily for 7, 14, and 21 days every 3 weeks as one cycle. The total dose per cycle was increased from 175 to 840 mg/m2. Eighteen patients were enrolled in this study. DLT occurred in one of six patients at 75 mg/m2/day × 7 days, and one of three patients at 37.5 mg/m2/day × 14 days and 25 mg/m2/day × 21 days. However, the delayed recovery from a decrease in neutrophil or platelet count hampered the start of subsequent treatment cycles, and the trend was more prominent at 37.5 mg/m2/day × 14 days and 25 mg/m2/day × 21 days than in 75 mg/m2/day × 7 days. MTD was determined as 75 mg/m2/day × 7 days to allow acceptable hematologic recovery. The pharmacokinetics of orally-administered bendamustine were generally dose-dependent; however, the inter-individual variability is relatively large. The major adverse events were hematologic toxicities; gastrointestinal disorders were generally mild. Adverse drug reactions did not lead to the discontinuation of the drug. A partial response was observed in two of six patients (prostatic small cell carcinoma and thymic carcinoma) at 75 mg/m2/day × 7 days. The RD and optimal dosing schedule of orally-administered bendamustine was 75 mg/m2 once daily for 7 days every 3 weeks for the treatment of advanced solid tumors. (Trial registration number ClinicalTrials.gov NCT03604679. Registration date July 27, 2018)." @default.
• W4308182479 created "2022-11-09" @default.
• W4308182479 creator A5004361618 @default.
• W4308182479 creator A5007258796 @default.
• W4308182479 creator A5008731625 @default.
• W4308182479 creator A5011710526 @default.
• W4308182479 creator A5021522674 @default.
• W4308182479 creator A5030587345 @default.
• W4308182479 creator A5033396027 @default.
• W4308182479 creator A5033895817 @default.
• W4308182479 creator A5038101792 @default.
• W4308182479 creator A5041593880 @default.
• W4308182479 creator A5046628885 @default.
• W4308182479 creator A5057467660 @default.
• W4308182479 creator A5058195283 @default.
• W4308182479 creator A5064206219 @default.
• W4308182479 creator A5088152418 @default.
• W4308182479 date "2022-11-04" @default.
• W4308182479 modified "2023-09-26" @default.
• W4308182479 title "Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study" @default.
• W4308182479 cites W13328401 @default.
• W4308182479 cites W1584622450 @default.
• W4308182479 cites W1976127594 @default.
• W4308182479 cites W1983285975 @default.
• W4308182479 cites W1986250794 @default.
• W4308182479 cites W2017214208 @default.
• W4308182479 cites W2039175138 @default.
• W4308182479 cites W2051933683 @default.
• W4308182479 cites W2064462031 @default.
• W4308182479 cites W2066086870 @default.
• W4308182479 cites W2067630104 @default.
• W4308182479 cites W2068927098 @default.
• W4308182479 cites W2074533771 @default.
• W4308182479 cites W2078603533 @default.
• W4308182479 cites W2085346499 @default.
• W4308182479 cites W2137087766 @default.
• W4308182479 cites W2142019712 @default.
• W4308182479 cites W2164092350 @default.
• W4308182479 cites W2169209759 @default.
• W4308182479 cites W2176913865 @default.
• W4308182479 cites W2469109222 @default.
• W4308182479 cites W2599050690 @default.
• W4308182479 cites W2761878534 @default.
• W4308182479 cites W2791345134 @default.
• W4308182479 cites W2799445517 @default.
• W4308182479 cites W2917537905 @default.
• W4308182479 cites W3048067521 @default.
• W4308182479 cites W3121328438 @default.
• W4308182479 cites W4205724345 @default.
• W4308182479 cites W75530370 @default.
• W4308182479 doi "https://doi.org/10.1007/s10637-022-01307-6" @default.
• W4308182479 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36331674" @default.
• W4308182479 hasPublicationYear "2022" @default.
• W4308182479 type Work @default.
• W4308182479 citedByCount "0" @default.
• W4308182479 crossrefType "journal-article" @default.
• W4308182479 hasAuthorship W4308182479A5004361618 @default.
• W4308182479 hasAuthorship W4308182479A5007258796 @default.
• W4308182479 hasAuthorship W4308182479A5008731625 @default.
• W4308182479 hasAuthorship W4308182479A5011710526 @default.
• W4308182479 hasAuthorship W4308182479A5021522674 @default.
• W4308182479 hasAuthorship W4308182479A5030587345 @default.
• W4308182479 hasAuthorship W4308182479A5033396027 @default.
• W4308182479 hasAuthorship W4308182479A5033895817 @default.
• W4308182479 hasAuthorship W4308182479A5038101792 @default.
• W4308182479 hasAuthorship W4308182479A5041593880 @default.
• W4308182479 hasAuthorship W4308182479A5046628885 @default.
• W4308182479 hasAuthorship W4308182479A5057467660 @default.
• W4308182479 hasAuthorship W4308182479A5058195283 @default.
• W4308182479 hasAuthorship W4308182479A5064206219 @default.
• W4308182479 hasAuthorship W4308182479A5088152418 @default.
• W4308182479 hasBestOaLocation W43081824791 @default.
• W4308182479 hasConcept C111113717 @default.
• W4308182479 hasConcept C112705442 @default.
• W4308182479 hasConcept C126322002 @default.
• W4308182479 hasConcept C162156334 @default.
• W4308182479 hasConcept C197934379 @default.
• W4308182479 hasConcept C2777288759 @default.
• W4308182479 hasConcept C2777334693 @default.
• W4308182479 hasConcept C2778715236 @default.
• W4308182479 hasConcept C2779338263 @default.
• W4308182479 hasConcept C2780653079 @default.
• W4308182479 hasConcept C2781442060 @default.
• W4308182479 hasConcept C29730261 @default.
• W4308182479 hasConcept C71924100 @default.
• W4308182479 hasConcept C90924648 @default.
• W4308182479 hasConcept C98274493 @default.
• W4308182479 hasConceptScore W4308182479C111113717 @default.
• W4308182479 hasConceptScore W4308182479C112705442 @default.
• W4308182479 hasConceptScore W4308182479C126322002 @default.
• W4308182479 hasConceptScore W4308182479C162156334 @default.
• W4308182479 hasConceptScore W4308182479C197934379 @default.
• W4308182479 hasConceptScore W4308182479C2777288759 @default.
• W4308182479 hasConceptScore W4308182479C2777334693 @default.
• W4308182479 hasConceptScore W4308182479C2778715236 @default.
• W4308182479 hasConceptScore W4308182479C2779338263 @default.
• W4308182479 hasConceptScore W4308182479C2780653079 @default.
• W4308182479 hasConceptScore W4308182479C2781442060 @default.

• next